Monash University's Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, has been honored with a 2025 Research Excellence Award from the National Health and Medical Research Council (NHMRC) of Australia.
Award Details
Professor Christopoulos received the 2025 NHMRC Peter Doherty Investigator Grant Award (Leadership). This prestigious award recognizes the highest-ranked recipient in the national Leadership category of Investigator Grants. NHMRC's Research Excellence Awards are presented annually to top-ranked researchers following peer review of applications to the NHMRC’s grant schemes.
Professor Christopoulos's award recognizes him as the highest-ranked recipient in the national Leadership category of Investigator Grants, a testament to his impactful research.
Research Focus
The award acknowledges Professor Christopoulos's impactful work at the Monash Institute of Pharmaceutical Sciences (MIPS). His research is dedicated to developing new classes of targeted medicines to address global health issues, specifically cognitive deficits associated with schizophrenia and Alzheimer’s Disease.
Professor Christopoulos's pioneering research focuses on G protein-coupled receptors (GPCRs), which are common protein targets for modern medicines. He explores novel 'allosteric' drug binding sites on these proteins, which are spatially distinct from the primary binding site used by natural hormones and neurochemicals. This multidisciplinary work integrates pharmacology, medicinal chemistry, mathematical modelling, structural and computational biology, and preclinical disease models to address major health burdens such as neuropsychiatric and neurological diseases, cardiovascular and metabolic diseases, chronic pain, and lymphatic dysfunction.
NHMRC Project
His NHMRC project is specifically titled “Allosteric modulation of muscarinic receptors for the treatment of neurocognitive deficits.” This research program targets a subset of GPCRs crucial for treating schizophrenia and Alzheimer’s disease, which have historically been resistant to standard drug targeting approaches. The project aims to overcome this challenge through cutting-edge structural, computational, chemical, pharmacological, and translational biology approaches to exploit alternative modes of targeting previously 'intractable' GPCRs.
Recognition and Impact
Professor Christopoulos has consistently been named a Clarivate Analytic ‘Highly Cited Researcher’ for over 12 years, highlighting his sustained influence in the scientific community. His profound contributions to pharmacology and drug discovery have also led to his election as a Fellow of the Australian Academy of Health and Medical Sciences in 2017 and to the Australian Academy of Science in 2021.